Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells.
You F, Jiang L, Zhang B, Lu Q, Zhou Q, Liao X, Wu H, Du K, Zhu Y, Meng H, Gong Z, Zong Y, Huang L, Lu M, Tang J, Li Y, Zhai X, Wang X, Ye S, Chen D, Yuan L, Qi L, Yang L.
You F, et al. Among authors: yang l.
Sci China Life Sci. 2016 Apr;59(4):386-97. doi: 10.1007/s11427-016-5024-7. Epub 2016 Mar 7.
Sci China Life Sci. 2016.
PMID: 26961900
Clinical Trial.